BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.540
+0.050 (3.36%)
At close: Mar 16, 2026, 4:00 PM EDT
1.530
-0.010 (-0.64%)
After-hours: Mar 16, 2026, 7:41 PM EDT

BioXcel Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-68.21-59.6-179.05-165.76-106.93-82.17
Depreciation & Amortization
0.30.310.320.330.30.19
Stock-Based Compensation
2.126.1618.6117.3419.4614.61
Other Adjustments
11.91-12.863.12.350.310.29
Change in Receivables
0-0.060.18-0.25--
Changes in Inventories
1.071.31-0.01-1.99--
Changes in Accounts Payable
-4.37-4.33-3.2213.034.853.2
Changes in Accrued Expenses
-0.04-0.742.53.8--
Changes in Other Operating Activities
-1.03-2.222.57-4.2-0.13-2.47
Operating Cash Flow
-58.21-72.03-155.01-135.34-82.15-66.35
Capital Expenditures
---0.02-0.14-0.45-0.32
Investing Cash Flow
---0.02-0.14-0.45-0.32
Long-Term Debt Issued
---98.6--
Long-Term Debt Repaid
--2.5----
Net Long-Term Debt Issued (Repaid)
--2.5-98.6--
Issuance of Common Stock
59.3839.6927.540.28102.45256.38
Repurchase of Common Stock
------9.02
Net Common Stock Issued (Repurchased)
59.3839.6927.540.28102.45247.36
Other Financing Activities
-1.73-0.53-1.02-2.65--
Financing Cash Flow
55.1536.6626.5296.24102.45247.36
Net Cash Flow
-3.07-35.37-128.5-39.2419.85180.69
Free Cash Flow
-58.21-72.03-155.03-135.48-82.6-66.67
FCF Margin
-7741.22%-3178.60%-11233.77%-36128.00%--
Free Cash Flow Per Share
-7.78-28.41-85.13-77.38-50.11-49.19
Levered Free Cash Flow
-72.28-67.76-176.91-56.32-102.36-81.57
Unlevered Free Cash Flow
-54.74-72.91-169.64-148.81-102.37-81.69
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q